These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35149547)

  • 1. The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
    Anastasia A; Dellavedova G; Ramos-Montoya A; James N; Chiorino G; Russo M; Baakza H; Wilson J; Ghilardi C; Cadogan EB; Giavazzi R; Bani MR
    Mol Cancer Ther; 2022 Apr; 21(4):555-567. PubMed ID: 35149547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
    Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
    Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
    Perez-Fidalgo JA; Cortés A; Guerra E; García Y; Iglesias M; Bohn Sarmiento U; Calvo García E; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
    ESMO Open; 2021 Aug; 6(4):100212. PubMed ID: 34329939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
    Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Teymori S; Minchinton AI
    DNA Repair (Amst); 2024 Jul; 139():103689. PubMed ID: 38749239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
    Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B
    J Clin Oncol; 2012 Feb; 30(4):372-9. PubMed ID: 22203755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
    Nakamura K; Karmokar A; Farrington PM; James NH; Ramos-Montoya A; Bickerton SJ; Hughes GD; Illidge TM; Cadogan EB; Davies BR; Dovedi SJ; Valge-Archer V
    Clin Cancer Res; 2021 Aug; 27(15):4353-4366. PubMed ID: 34011558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
    Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
    Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-
    Goldberg FW; Finlay MRV; Ting AKT; Beattie D; Lamont GM; Fallan C; Wrigley GL; Schimpl M; Howard MR; Williamson B; Vazquez-Chantada M; Barratt DG; Davies BR; Cadogan EB; Ramos-Montoya A; Dean E
    J Med Chem; 2020 Apr; 63(7):3461-3471. PubMed ID: 31851518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
    Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
    BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
    Del Conte G; Sessa C; von Moos R; Viganò L; Digena T; Locatelli A; Gallerani E; Fasolo A; Tessari A; Cathomas R; Gianni L
    Br J Cancer; 2014 Aug; 111(4):651-9. PubMed ID: 25025963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
    Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
    Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
    Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
    PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
    Dellavedova G; Decio A; Formenti L; Albertella MR; Wilson J; Staniszewska AD; Leo E; Giavazzi R; Ghilardi C; Bani MR
    Cancer Res Commun; 2023 Mar; 3(3):489-500. PubMed ID: 36994441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648.
    Hong CR; Buckley CD; Wong WW; Anekal PV; Dickson BD; Bogle G; Hicks KO; Hay MP; Wilson WR
    Radiother Oncol; 2022 Jan; 166():162-170. PubMed ID: 34861268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
    Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
    Mantia-Smaldone G; Ronner L; Blair A; Gamerman V; Morse C; Orsulic S; Rubin S; Gimotty P; Adams S
    Gynecol Oncol; 2014 Jun; 133(3):584-90. PubMed ID: 24680909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
    Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
    Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.